Vincenzo Mazzaferro
Overview
Explore the profile of Vincenzo Mazzaferro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
334
Citations
23664
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peng Y, Liu F, Li B, Wei Y, Tan H, Syn N, et al.
Eur J Surg Oncol
. 2025 Mar;
51(6):109597.
PMID: 40088501
Introduction: The Iwate difficulty scoring system (DSS) is one of the most widely validated DSS for laparoscopic liver resection (LLR). However, these studies only validated the 4 difficulty levels and...
2.
Citterio D, Droz Dit Busset M, Sposito C, Mazzola M, Grandi S, Zironda A, et al.
Surg Oncol
. 2025 Mar;
59:102208.
PMID: 40086295
Background: Long-term survival after resection for pancreatic ductal adenocarcinoma (PDAC) is impaired by very high recurrence rates. When recurrence occurs within 6 months (early recurrence: ER) the benefit of surgery...
3.
Angelico R, Trapani S, Manzia T, Lenci I, Grossi P, Ricci A, et al.
Am J Transplant
. 2025 Mar;
PMID: 40057194
Patients with HDV/HBV-related end-stage liver disease candidates for liver transplantation(LT) have traditionally been regarded as a special population, although their outcomes are controversial. A intention-to-treat(ITT) analysis of long-term outcomes of...
4.
Liver transplantation for HBV-related liver disease: Impact of prophylaxis for HBV on HCC recurrence
Burra P, Battistella S, Turco L, Morelli M, Frassanito G, De Maria N, et al.
JHEP Rep
. 2025 Mar;
7(3):101278.
PMID: 40041120
Background & Aims: Conflicting data exist regarding optimal prophylaxis for HBV recurrence (HBV-R) after liver transplantation (LT), particularly in patients with hepatocellular carcinoma (HCC). We assessed current practices for HBV-R...
5.
Tabrizian P, Marino R, Bhoori S, Zeitlhoefler M, Mehta N, Banz V, et al.
JHEP Rep
. 2025 Feb;
7(2):101246.
PMID: 39911942
Background & Aims: The combination of atezolizumab and bevacizumab offers a novel approach to immunomodulation, showing efficacy as a primary treatment in advanced hepatocellular carcinoma (HCC). Concerns about graft safety...
6.
Magyar C, OKane G, Aceituno L, Li Z, Vogel A, Bruix J, et al.
J Clin Oncol
. 2024 Dec;
43(5):589-604.
PMID: 39680821
Liver transplantation (LT) has been accepted as a cornerstone of care in hepatocellular carcinoma (HCC) for almost three decades. In recent years, its role has been evolving to include patients...
7.
Asmundo L, Giaccardi L, Soro A, Lanocita R, Buonomenna C, Vigorito R, et al.
Eur J Radiol
. 2024 Dec;
183:111869.
PMID: 39647273
Solitary necrotic nodule of the liver (SNNL) is a rare and benign liver lesion often discovered incidentally. Despite its occurrence, the exact cause of SNNL remains unknown, with various theories...
8.
Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, et al.
Cancer Med
. 2024 Dec;
13(23):e70393.
PMID: 39618336
Background: The identification of actionable molecular targets of pancreatic cancer (PAC) is key to improving patient outcomes. We hypothesized O6-methylguanine-DNA methyltransferase (MGMT) silencing may occur in a subset of PAC...
9.
Magyar C, Arteaga N, Germani G, Karam V, Adam R, Romagnoli R, et al.
Liver Int
. 2024 Nov;
45(1):e16178.
PMID: 39564600
Background & Aims: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Liver transplantation (LT) is a curative treatment option. We investigated survival outcomes based on recipient-donor...
10.
Maspero M, Sposito C, Bongini M, Cascella T, Flores M, Maccauro M, et al.
Transpl Int
. 2024 Nov;
37:13641.
PMID: 39544321
Liver transplantation (LT) is a potentially curative experimental treatment for unresectable intrahepatic cholangiocarcinoma (iCC). Pre-transplant downstaging may help defining tumor aggressiveness and drive patient selection. We report the preliminary results...